Pimodivir - Janssen Pharmaceuticals

Drug Profile

Pimodivir - Janssen Pharmaceuticals

Alternative Names: JNJ-3872; JNJ-63623872; JNJ-872; VX 787

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Janssen Pharmaceuticals; Vertex Pharmaceuticals
  • Class Antivirals; Pyridines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Viral protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Influenza A virus infections

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for phase-I development in Influenza-A-virus-infections(In volunteers) in Netherlands (PO, Tablet)
  • 21 Apr 2018 Adverse events and efficacy data from two phase IIb trials in Influenza-A virus infections presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
  • 18 Jan 2018 Janssen Research & Development initiates enrolment in a phase III trial for Influenza-A virus infections (In adolescents, In adults, In the elderly, Combination therapy) in USA (PO) (NCT03381196)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top